NASHVILLE, Tenn., Nov. 1, 2016/PRNewswire/ - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a strength pharmaceutical organization concentrated on healing facility intense care and gastroenterology, today declared second from last quarter 2016 money related results with Net Revenues of $8.8 million and Adjusted Earnings of $1.0 million or $0.06 per share. Profit before modification were $0.1 million or $0.01 per share.
As of September 30, 2016, the Company had roughly $91 million in Total Assets incorporating $50 million in real money and attractive securities. Add up to Liabilities were around $17 million and Total Shareholder's Equity was just shy of $75 million. Cumberland additionally had roughly $43 million in assessment net working misfortune carryforwards, coming about because of the earlier practice of investment opportunities.
Keep Reading
Cumberland Pharmaceuticals Logo
Cumberland Pharmaceuticals Logo
QUARTER HIGHLIGHTS:
Propelled Ethyol®, a FDA endorsed cytoprotective medication and Cumberland's first oncology item, in the United States.
Started a fourth ifetroban clinical program, with FDA leeway for an IND - to create Portaban™ for the treatment of entryway hypertension.
Invited Caroline Young, previous president of the Nashville Health Care Council, to the Company's Board of Directors.
"We have been occupied with setting up the pieces to construct our business energy while growing our clinical pipeline and keeping up a solid money related position," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We entered the second 50% of 2016 with restored energy and stay concentrated on our key working targets which we accept will take the organization to the following level."
Late DEVELOPMENTS:
Ethyol®
Cumberland propelled Ethyol® (amifostine) for Injection in the United States at a National Meeting of the Company's business association in September. Ethyol is a FDA affirmed healing center item used to bolster the care of oncology patients. It is a cytoprotective medication showed to bolster choose patients experiencing radiation treatment and in addition those experiencing chemotherapy for specific tumors. At the National Sales Meeting, Cumberland's healing facility deals association was prepared and arranged to reintroduce marked amifostine to another era of oncologists. Throughout the previous quite a while, no organization has been instructing doctors on the advantages of this item for their patients.
This is the principal item to be authorized by Cumberland from Clinigen Group plc under the Strategic Alliance went into a year ago furthermore Cumberland's first oncology item. Under the terms of the Ethyol permit understanding, Cumberland is in charge of all circulation, advertising, advancement, and medicinal support of the item in the U.S.
Portaban™
Cumberland declared its fourth clinical advancement program for ifetroban to create Portaban™, an oral type of ifetroban, for the treatment of entry hypertension connected with liver malady. Gateway hypertension, a complexity of liver cirrhosis, is an expansion in the circulatory strain inside the entry venous framework. This expanded weight in the entry veins may prompt to the advancement of huge, swollen veins which can break and drain, bringing about possibly life-debilitating complexities. Preclinical studies have demonstrated that ifetroban can diminish gateway weight, irritation, and fibrosis in various models of liver harm.
The U.S. Nourishment and Drug Administration has cleared Cumberland's investigational new medication application, or IND, for a Phase II clinical investigation of Portaban. The Company is get ready for the study, anticipated that would start later this fall.
Monetary RESULTS:
Net Revenue: For the three months finished September 30, 2016, net incomes were $8.8 million, contrasted with $7.9 million for the earlier year time frame. Net income by item for the three months finished September 30, 2016, included $3.7 million for Kristalose®, $1.8 million for Acetadote®, including $1.2 million for the Company's Authorized Generic, $1.4 million for Caldolor®, $0.8 million for Omeclamox®-Pak, $0.5 million for Vaprisol®, and $0.5 million for Ethyol®.
For the nine months finished September 30, 2016, net incomes were $23.9 million contrasted with $25.5 million for the nine months finished September 30, 2015.
Working Expenses: Total working costs for the three months finished September 30, 2016 were $8.7 million, contrasted with $7.6 million amid the earlier year time frame. Add up to working costs for the initial nine months of 2016 were $24.4 million like $24.5 million for 2015.
Profit: Net pay for the second from last quarter of 2016 was $0.1 million and $0.01 per weakened share, like the earlier year time frame. Balanced Earnings for the second from last quarter were $1.0 million or $0.06 per share, contrasted with $0.7 million or $0.04 per share for the earlier year time frame. The definition and compromise of Adjusted Earnings to net wage is given in this discharge.
Monetary record: At September 30, 2016, Cumberland had $50.1 million in real money and attractive securities, with around $35.5 million in real money and counterparts and $14.6 million in attractive securities. Add up to Assets at September 30, 2016 were $91.1 million. Add up to Liabilities were $16.7 million, including $3.7 million remarkable on our spinning credit extension, bringing about Total Shareholder's Equity of $74.5 million. Cumberland additionally had roughly $43 million in cockeyed sheet charge net working misfortune carryforwards, coming about because of the earlier practice of investment opportunities.
Telephone call and Webcast
A telephone call and live Internet webcast will be hung on Tuesday, November 1, 2016 at 4:30 p.m. Eastern Time to examine the Company's second from last quarter 2016 money related results. To take an interest in the call, please dial 877-303-1298 (for U.S. guests) or 253-237-1032 (for universal guests). A rebroadcast of the video chat will be accessible for one week and can be gotten to by dialing 855-859-2056 (for U.S. guests) or 404-537-3406 (for global guests). The Conference ID for the rebroadcast is 99386514. The live webcast and rebroadcast can be gotten to by means of Cumberland's site at http://investor.shareholder.com/cpix/events.cfm.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a forte pharmaceutical organization concentrated on securing, improvement, and commercialization of marked remedy items. The Company's essential target markets incorporate healing facility intense care and gastroenterology. Cumberland's six showcased items incorporate Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen harming, Caldolor® (ibuprofen) Injection, for the treatment of torment and fever, Kristalose® (lactulose) for Oral Solution, a medicine purgative, Vaprisol® (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak® for the treatment of H. pylori contamination and duodenal ulcer sickness, and Ethyol® (amifostine) for Injection, for the treatment of oncology patients.
Cumberland is creating Hepatoren® (ifetroban) Injection for the treatment of Hepatorenal Syndrome, Boxaban® (ifetroban) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease, Vasculan™ (ifetroban) Oral Capsule for the treatment of systemic sclerosis, and Portaban™, for the treatment of entry hypertension.
Cumberland is devoted to giving imaginative items that enhance nature of nurture patients. For more data on Cumberland's affirmed items, including full endorsing data, please visit the individual item sites, connections to which can be found on the Company's site www.cumberlandpharma.com.
About Acetadote® (acetylcysteine) Injection
Acetadote, directed intravenously inside 8 to 10 hours after ingestion of a conceivably hepatotoxic amount of acetaminophen, is demonstrated to anticipate or reduce hepatic harm. Utilized as a part of the crisis division, Acetadote is endorsed in the United States to treat overdose of acetaminophen, a typical fixing in numerous over-the-counter solutions. Acetadote is contraindicated in patients with touchiness or past anaphylactoid responses to acetylcysteine or any segments of the arrangement. Genuine anaphylactoid responses, incorporating demise in a patient with asthma, have been accounted for in patients controlled acetylcysteine intravenously. Acetadote ought to be utilized with alert as a part of patients with asthma or where there is a past filled with bronchospasm. The aggregate volume regulated ought to be balanced for patients weighing under 40 kg and for those requiring liquid confinement. To maintain a strategic distance from liquid over-burden, the volume of diluent ought to be lessened as required. In the event that volume is not balanced, liquid over-burden can happen, possibly bringing about hyponatremia, seizure, and passing. For full recommending data, visit www.acetadote.com.
About Caldolor® (ibuprofen) Injection
Caldolor is shown in grown-ups and pediatric patients for the administration of gentle to direct agony and administration of direct to extreme torment as a subordinate to opioid analgesics, and in addition the lessening of fever. It was the main FDA-endorsed intravenous treatment for fever. Caldolor is contraindicated in patients with known touchiness to ibuprofen or different NSAIDs, patients with a past filled with asthma or other unfavorably susceptible sort responses in the wake of taking headache medicine or different NSAIDs. Caldolor is contraindicated for use amid the peri-agent period in the setting of coronary vein sidestep unite (CABG) surgery. Caldolor ought to be utilized with alert as a part of patients with earlier history of ulcer ailment or GI seeping, in patients with liquid maintenance or heart disappointment, in the elderly, those with renal disability, heart disappointment, liver debilitation, and those taking diuretics or ACE inhibitors. Circulatory strain ought to be checked amid treatment with Caldolor. For full endorsing data, including boxed cautioning, visit www.caldolor.com.
About
As of September 30, 2016, the Company had roughly $91 million in Total Assets incorporating $50 million in real money and attractive securities. Add up to Liabilities were around $17 million and Total Shareholder's Equity was just shy of $75 million. Cumberland additionally had roughly $43 million in assessment net working misfortune carryforwards, coming about because of the earlier practice of investment opportunities.
Keep Reading
Cumberland Pharmaceuticals Logo
Cumberland Pharmaceuticals Logo
QUARTER HIGHLIGHTS:
Propelled Ethyol®, a FDA endorsed cytoprotective medication and Cumberland's first oncology item, in the United States.
Started a fourth ifetroban clinical program, with FDA leeway for an IND - to create Portaban™ for the treatment of entryway hypertension.
Invited Caroline Young, previous president of the Nashville Health Care Council, to the Company's Board of Directors.
"We have been occupied with setting up the pieces to construct our business energy while growing our clinical pipeline and keeping up a solid money related position," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We entered the second 50% of 2016 with restored energy and stay concentrated on our key working targets which we accept will take the organization to the following level."
Late DEVELOPMENTS:
Ethyol®
Cumberland propelled Ethyol® (amifostine) for Injection in the United States at a National Meeting of the Company's business association in September. Ethyol is a FDA affirmed healing center item used to bolster the care of oncology patients. It is a cytoprotective medication showed to bolster choose patients experiencing radiation treatment and in addition those experiencing chemotherapy for specific tumors. At the National Sales Meeting, Cumberland's healing facility deals association was prepared and arranged to reintroduce marked amifostine to another era of oncologists. Throughout the previous quite a while, no organization has been instructing doctors on the advantages of this item for their patients.
This is the principal item to be authorized by Cumberland from Clinigen Group plc under the Strategic Alliance went into a year ago furthermore Cumberland's first oncology item. Under the terms of the Ethyol permit understanding, Cumberland is in charge of all circulation, advertising, advancement, and medicinal support of the item in the U.S.
Portaban™
Cumberland declared its fourth clinical advancement program for ifetroban to create Portaban™, an oral type of ifetroban, for the treatment of entry hypertension connected with liver malady. Gateway hypertension, a complexity of liver cirrhosis, is an expansion in the circulatory strain inside the entry venous framework. This expanded weight in the entry veins may prompt to the advancement of huge, swollen veins which can break and drain, bringing about possibly life-debilitating complexities. Preclinical studies have demonstrated that ifetroban can diminish gateway weight, irritation, and fibrosis in various models of liver harm.
The U.S. Nourishment and Drug Administration has cleared Cumberland's investigational new medication application, or IND, for a Phase II clinical investigation of Portaban. The Company is get ready for the study, anticipated that would start later this fall.
Monetary RESULTS:
Net Revenue: For the three months finished September 30, 2016, net incomes were $8.8 million, contrasted with $7.9 million for the earlier year time frame. Net income by item for the three months finished September 30, 2016, included $3.7 million for Kristalose®, $1.8 million for Acetadote®, including $1.2 million for the Company's Authorized Generic, $1.4 million for Caldolor®, $0.8 million for Omeclamox®-Pak, $0.5 million for Vaprisol®, and $0.5 million for Ethyol®.
For the nine months finished September 30, 2016, net incomes were $23.9 million contrasted with $25.5 million for the nine months finished September 30, 2015.
Working Expenses: Total working costs for the three months finished September 30, 2016 were $8.7 million, contrasted with $7.6 million amid the earlier year time frame. Add up to working costs for the initial nine months of 2016 were $24.4 million like $24.5 million for 2015.
Profit: Net pay for the second from last quarter of 2016 was $0.1 million and $0.01 per weakened share, like the earlier year time frame. Balanced Earnings for the second from last quarter were $1.0 million or $0.06 per share, contrasted with $0.7 million or $0.04 per share for the earlier year time frame. The definition and compromise of Adjusted Earnings to net wage is given in this discharge.
Monetary record: At September 30, 2016, Cumberland had $50.1 million in real money and attractive securities, with around $35.5 million in real money and counterparts and $14.6 million in attractive securities. Add up to Assets at September 30, 2016 were $91.1 million. Add up to Liabilities were $16.7 million, including $3.7 million remarkable on our spinning credit extension, bringing about Total Shareholder's Equity of $74.5 million. Cumberland additionally had roughly $43 million in cockeyed sheet charge net working misfortune carryforwards, coming about because of the earlier practice of investment opportunities.
Telephone call and Webcast
A telephone call and live Internet webcast will be hung on Tuesday, November 1, 2016 at 4:30 p.m. Eastern Time to examine the Company's second from last quarter 2016 money related results. To take an interest in the call, please dial 877-303-1298 (for U.S. guests) or 253-237-1032 (for universal guests). A rebroadcast of the video chat will be accessible for one week and can be gotten to by dialing 855-859-2056 (for U.S. guests) or 404-537-3406 (for global guests). The Conference ID for the rebroadcast is 99386514. The live webcast and rebroadcast can be gotten to by means of Cumberland's site at http://investor.shareholder.com/cpix/events.cfm.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a forte pharmaceutical organization concentrated on securing, improvement, and commercialization of marked remedy items. The Company's essential target markets incorporate healing facility intense care and gastroenterology. Cumberland's six showcased items incorporate Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen harming, Caldolor® (ibuprofen) Injection, for the treatment of torment and fever, Kristalose® (lactulose) for Oral Solution, a medicine purgative, Vaprisol® (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak® for the treatment of H. pylori contamination and duodenal ulcer sickness, and Ethyol® (amifostine) for Injection, for the treatment of oncology patients.
Cumberland is creating Hepatoren® (ifetroban) Injection for the treatment of Hepatorenal Syndrome, Boxaban® (ifetroban) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease, Vasculan™ (ifetroban) Oral Capsule for the treatment of systemic sclerosis, and Portaban™, for the treatment of entry hypertension.
Cumberland is devoted to giving imaginative items that enhance nature of nurture patients. For more data on Cumberland's affirmed items, including full endorsing data, please visit the individual item sites, connections to which can be found on the Company's site www.cumberlandpharma.com.
About Acetadote® (acetylcysteine) Injection
Acetadote, directed intravenously inside 8 to 10 hours after ingestion of a conceivably hepatotoxic amount of acetaminophen, is demonstrated to anticipate or reduce hepatic harm. Utilized as a part of the crisis division, Acetadote is endorsed in the United States to treat overdose of acetaminophen, a typical fixing in numerous over-the-counter solutions. Acetadote is contraindicated in patients with touchiness or past anaphylactoid responses to acetylcysteine or any segments of the arrangement. Genuine anaphylactoid responses, incorporating demise in a patient with asthma, have been accounted for in patients controlled acetylcysteine intravenously. Acetadote ought to be utilized with alert as a part of patients with asthma or where there is a past filled with bronchospasm. The aggregate volume regulated ought to be balanced for patients weighing under 40 kg and for those requiring liquid confinement. To maintain a strategic distance from liquid over-burden, the volume of diluent ought to be lessened as required. In the event that volume is not balanced, liquid over-burden can happen, possibly bringing about hyponatremia, seizure, and passing. For full recommending data, visit www.acetadote.com.
About Caldolor® (ibuprofen) Injection
Caldolor is shown in grown-ups and pediatric patients for the administration of gentle to direct agony and administration of direct to extreme torment as a subordinate to opioid analgesics, and in addition the lessening of fever. It was the main FDA-endorsed intravenous treatment for fever. Caldolor is contraindicated in patients with known touchiness to ibuprofen or different NSAIDs, patients with a past filled with asthma or other unfavorably susceptible sort responses in the wake of taking headache medicine or different NSAIDs. Caldolor is contraindicated for use amid the peri-agent period in the setting of coronary vein sidestep unite (CABG) surgery. Caldolor ought to be utilized with alert as a part of patients with earlier history of ulcer ailment or GI seeping, in patients with liquid maintenance or heart disappointment, in the elderly, those with renal disability, heart disappointment, liver debilitation, and those taking diuretics or ACE inhibitors. Circulatory strain ought to be checked amid treatment with Caldolor. For full endorsing data, including boxed cautioning, visit www.caldolor.com.
About
No comments:
Post a Comment
Note: only a member of this blog may post a comment.